Announcements Trials
Browse Landscape

Status

No longer available 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 273Observational 52Expanded_access 2

Sponsor

Cancer Type

Breast 18Gastrointestinal 5Thoracic 4Genitourinary 4Gynecologic 3Sarcoma 2Head & Neck 2CNS 2Lymphoid 1Endocrine 1Dermatologic 1

Conditions

Glioblastoma 15Neuroblastoma 13Glioma 11Pheochromocytoma 7Neoplasms 6Recurrence 5Paraganglioma 5Pancreatic Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neuroectodermal Tumors, Primitive 2Medulloblastoma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Astrocytoma 2Wilms Tumor 1Urinary Bladder Neoplasms 1Typical Teratoid Rhabdoid Tumor 1Thyroid cancer, medullary 1Thyroid Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1

Interventions

tucatinib 1Proton Pump Inhibitors 1Hydrocortisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Breast Neoplasms × CNS × Clear all
NCT05974410 2025-10-02

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

AVM Biotechnology Inc

Available
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Brain Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Glioblastoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms

NCT03424473 2020-02-25

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Seagen Inc.

No longer available
BreastCNS

Brain Neoplasms, Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡